[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Life Force of Tampa, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":57},{"warningLetters":4,"total":56},[5,33],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},2467,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-09-06T13:20:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-04T04:00:00Z\">08\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fleaf-life-llc-619191-08042022\">Leaf of Life LLC\u003C\u002Fa>","Office of Human and Animal Food- West Division II","Unapproved New Drugs\u002FMisbranded","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fleaf-life-llc-619191-01182023\">\u003Ctime datetime=\"2023-01-23T05:00:00Z\">01\u002F23\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Alexander Bolin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Leaf of Life LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4419 S. Kingshighway Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>St. Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food- West Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 4, 2022\u003C\u002Fp>\n\n\u003Cp>FEI: 3015401107\u003Cbr>\nReference CMS # 619191\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bolin:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.kokatonic.com in July 2022 and has determined that you take orders there for the products Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>The following statements were found under the benefits tab of your website:\u003C\u002Fp>\n\n\u003Cp>Coca [an ingredient in the products Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk] “is a plant with a complex array of mineral nutrients, essential oils, and varied compounds with greater or lesser effects. It can:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Reduces Eating Anxiety Issues\u003C\u002Fli>\n\t\u003Cli>Regulates Blood Glucose\u003C\u002Fli>\n\t\u003Cli>Lower Risks of Cardiovascular Disease\u003C\u002Fli>\n\t\u003Cli>Regulates Blood Pressure\u003C\u002Fli>\n\t\u003Cli>Extraordinarily Combats Anemia\u003C\u002Fli>\n\t\u003Cli>Arthritis and Osteoporosis Relief\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your YouTube Channel at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=_ulGmMXVi8s, the video titled Kokatonic Coca Leaf Song Instrumental Official Video posted on Sep 25, 2019, states the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“COCA LEAF REDUCES EATING ANXIETY ISSUES” at approximately 0:43sec in the video\u003C\u002Fli>\n\t\u003Cli>“COCA LEAF LOWERS RISKS OF CARDIVASCULAR DISEASE” at approximately 1m:28sec in the video\u003C\u002Fli>\n\t\u003Cli>“COCA LEAF REGULATES BLOOD PRESSURE &amp; BLOOD GLUCOSE” at approximately 1m:45sec in the video\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO (Fresh New) 250g\u002FBag Coca Powder Delisse, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina de LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act [ 21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, 8050 Marshall Drive, Suite 205, Lenexa, Kansas 66214, to the attention of Bruce E. Taylor, Compliance Officer. If you need additional information or have questions concerning any products distributed through your website, please contact CO Taylor at 913-495-5114 or at the above address or via email at: bruce.taylor@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>LaTonya M. Mitchell, Ph.D.\u003Cbr>\nDistrict Director | FDA Kansas City District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Foods – West Division 2\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Alexander Bolin\n\nRecipient Title\n\nCEO\n\nLeaf of Life LLC\n\n4419 S. Kingshighway Blvd.\n\nSt. Louis, MO 63109\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food- West Division II\n\nUnited States\n\nAugust 4, 2022\n\nFEI: 3015401107\n\nReference CMS # 619191\n\nWARNING LETTER\n\nDear Mr. Bolin:\n\nThis letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.kokatonic.com in July 2022 and has determined that you take orders there for the products Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nThe following statements were found under the benefits tab of your website:\n\nCoca [an ingredient in the products Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk] “is a plant with a complex array of mineral nutrients, essential oils, and varied compounds with greater or lesser effects. It can:\n\nReduces Eating Anxiety Issues\n\nRegulates Blood Glucose\n\nLower Risks of Cardiovascular Disease\n\nRegulates Blood Pressure\n\nExtraordinarily Combats Anemia\n\nArthritis and Osteoporosis Relief\n\nOn your YouTube Channel at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=_ulGmMXVi8s, the video titled Kokatonic Coca Leaf Song Instrumental Official Video posted on Sep 25, 2019, states the following:\n\n“COCA LEAF REDUCES EATING ANXIETY ISSUES” at approximately 0:43sec in the video\n\n“COCA LEAF LOWERS RISKS OF CARDIVASCULAR DISEASE” at approximately 1m:28sec in the video\n\n“COCA LEAF REGULATES BLOOD PRESSURE & BLOOD GLUCOSE” at approximately 1m:45sec in the video\n\nYour Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO (Fresh New) 250g\u002FBag Coca Powder Delisse, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina de LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act [ 21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nMisbranded Drugs\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Kokatonic 50 grams Coca Leaf Powder, HOJA DE COCA NATURAL EN POLVO Delisse (Fresh New) 250g\u002FBag Coca Powder, and Delisse HOJA DE COCA MICROPULVERIZADO Del CUSCO al MUNDO Harina del LOS Inkas 100% Natural 500 grams Coca Leaf Powder Bulk fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, 8050 Marshall Drive, Suite 205, Lenexa, Kansas 66214, to the attention of Bruce E. Taylor, Compliance Officer. If you need additional information or have questions concerning any products distributed through your website, please contact CO Taylor at 913-495-5114 or at the above address or via email at: bruce.taylor@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLaTonya M. Mitchell, Ph.D.\n\nDistrict Director | FDA Kansas City District\n\nProgram Division Director\n\nOffice of Human and Animal Foods – West Division 2","Leaf of Life LLC","leaf-life-llc-619191-08042022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fleaf-life-llc-619191-08042022","2026-10-26T08:09:13.10086+00:00","Warning Letter","Closed Out","2022-09-06","619191","Drugs","2023-01-23","Michael Alexander Bolin","2026-08-20T01:36:41.739+00:00","VIA UPS","2022-08-04",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":52,"body_fetched_at":53,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":55,"medical_device_id":20,"response_letter_date":20},69,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-15T04:00:00Z\">06\u002F15\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flife-food-inc-731887-06152026\">Life &amp; Food Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Duncan Zheng\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FDirector   \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Life &amp; Food Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1050 E Flamingo Road, #S107 #2094\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89119-7427\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@lifefoodpro.com\"> sales@lifefoodpro.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 15, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 731887\u003C\u002Fp>\u003Cp>Dear Mr. Zheng:\u003C\u002Fp>\u003Cp>From May 4, 2026, through May 7, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Life &amp; Food Inc., located at 1050 E Flamingo Road, #S107 #2094, Las Vegas, NV 89119-7427. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response, dated May 14, 2026, in which you stated that Life &amp; Food Inc. operates as a Very Small Importer (VSI) and follows modified requirements. You also provided VSI Eligibility Declarations for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and written assurances for your foreign suppliers, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We are unable to evaluate the adequacy of your response because you have not provided supporting documentation demonstrating your corrective actions. Specifically, you did not provide documentation such as tax forms or income statements to substantiate your VSI eligibility. Additionally, the written assurances you submitted appear to be templates prepared by your firm rather than independent documents provided by your foreign suppliers. Furthermore, even if you meet the definition of a VSI, you are still required to develop and maintain a written FSVP, which you have not provided. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Midori Spring Gold Organic Ceremonial Matcha, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Green Tea, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Matcha Green Tea, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection, you indicated you choose to comply with the requirements for very small importers and may meet the definition of a “very small importer” under 21 CFR 1.500. If you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of a very small importer as required by 21 CFR 1.512(b)(1)(i). You are also still required to comply with the requirements in sections 1.502, 1.503, and 1.509. However, you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every 2 years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 731887 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDuncan Zheng\n\nRecipient Title\n\nOwner\u002FDirector\n\nLife & Food Inc.\n\n1050 E Flamingo Road, #S107 #2094\n\nLas Vegas, NV 89119-7427\n\nUnited States\n\nsales@lifefoodpro.com\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nJune 15, 2026\nWARNING LETTER\nRe: CMS # 731887\nDear Mr. Zheng:\nFrom May 4, 2026, through May 7, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Life & Food Inc., located at 1050 E Flamingo Road, #S107 #2094, Las Vegas, NV 89119-7427. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response, dated May 14, 2026, in which you stated that Life & Food Inc. operates as a Very Small Importer (VSI) and follows modified requirements. You also provided VSI Eligibility Declarations for (b)(4), and written assurances for your foreign suppliers, (b)(4), and (b)(4). We are unable to evaluate the adequacy of your response because you have not provided supporting documentation demonstrating your corrective actions. Specifically, you did not provide documentation such as tax forms or income statements to substantiate your VSI eligibility. Additionally, the written assurances you submitted appear to be templates prepared by your firm rather than independent documents provided by your foreign suppliers. Furthermore, even if you meet the definition of a VSI, you are still required to develop and maintain a written FSVP, which you have not provided. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nMidori Spring Gold Organic Ceremonial Matcha, imported from (b)(4), located in (b)(4).\nGreen Tea, imported from (b)(4), located in (b)(4).\nMatcha Green Tea, imported from (b)(4), located in (b)(4).\nDuring our inspection, you indicated you choose to comply with the requirements for very small importers and may meet the definition of a “very small importer” under 21 CFR 1.500. If you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of a very small importer as required by 21 CFR 1.512(b)(1)(i). You are also still required to comply with the requirements in sections 1.502, 1.503, and 1.509. However, you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every 2 years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 731887 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","Life & Food Inc.","life-food-inc-731887-06152026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flife-food-inc-731887-06152026","2026-10-26T08:09:14.335118+00:00","Issued","2026-06-30","731887","Food & Beverages","Duncan Zheng","2026-08-19T04:32:41.794+00:00","Via Express Delivery","2026-06-15",2,{"510k":58,"classification":59,"enforcement":60,"event":61,"event_backfill":62,"pma":63,"warning_letter":64},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]